Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort

Fig. 1

Drug survival of the second tumor necrosis factor inhibitor (TNFi), stratified by the reason for discontinuation of the first TNFi, in patients with a clinical diagnosis of axial spondyloarthritis. Other refers to reason for discontinuation other than lack of effect or intolerance. AE adverse events, PLR primary lack of response, SLR secondary lack of response

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us